Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.
| Last: | $25.28 |
|---|---|
| Change Percent: | 31.15% |
| Open: | $22.96 |
| Close: | $19.275 |
| High: | $26.3999 |
| Low: | $20.5 |
| Volume: | 928,470 |
| Last Trade Date Time: | 02/27/2026 12:45:37 pm |
| Market Cap: | $263,326,600 |
|---|---|
| Float: | 13,686,787 |
| Insiders Ownership: | 0.57% |
| Institutions: | 9 |
| Short Percent: | N/A |
| Industry: | Pharmaceuticals |
| Sector: | Healthcare |
| Website: | https://www.neurogene.com |
| Country: | US |
| City: | New York |
Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI FAQ is based on asking OpenAI questions about Neurogene Inc. (NASDAQ: NGNE).
Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.
Get instant news alerts to your mobile device as soon as the news hits the wire. Simply add a stock symbol to your portfolio and our service will alert you anytime there is news.
